Navigation Links
Kewaunee Scientific Reports Record Sales and Earnings for First Quarter

STATESVILLE, N.C., Aug. 27, 2013 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported record sales and earnings for its first quarter ended July 31, 2013.

Net earnings for the quarter were $1,587,000 or $0.61 per diluted share, up from net earnings of $634,000, or $0.25 per diluted share, in the first quarter of the prior year. Sales for the quarter were $32,003,000, up 19.9% from sales of $26,683,000 in the first quarter last year. Earnings for the quarter benefited from higher sales and earnings from both Domestic and International Operations, as well as the favorable impact of the Company's buyout of the minority ownership in its principal international subsidiary.

During the quarter, the Company purchased the 49% minority ownership of its subsidiary, Kewaunee Labway Asia Pte. Ltd. The purchase of this additional ownership increased net earnings for the quarter by $140,000, or $0.05 per diluted share. Through its headquarters in Singapore and its subsidiary in India, Kewaunee Labway Asia serves as the Company's international center for sales and installation of laboratory furniture products and fume hoods.

Domestic Operations sales for the quarter were $27,073,000, up 19.6% from sales of $22,629,000 in the first quarter last year. Sales benefited from strong order activity from the Company's dealer network and a strong backlog of orders with customer ship dates during the quarter. In the domestic markets, increased activity for mid-size private sector laboratory construction projects more than offset fewer large projects and continued soft demand for publicly funded wood projects. The Company continues to increase market share, although pricing remains very competitive in all of its market segments.

International Operations sales for the quarter were $4,930,000, up 21.6% from sales of $4,054,000 in the first quarter last year. The Company continues to see good opportunities in the international markets, particularly in the growth markets of India, the Middle East, and Singapore.

The order backlog was $71.1 million at July 31, 2013, as compared to $80.2 million at April 30, 2013. The lower order backlog reflects several factors, including the composition of the Domestic backlog, which continues to transition to a higher percentage of orders received through the Company's dealer organization. These orders typically remain in the backlog for a shorter duration. The backlog also reflects the manufacturing and shipment of a large International project during the quarter that had been in the backlog for an extended period due to construction project delays. The Company continues to aggressively pursue laboratory project opportunities, both domestically and internationally.

The Company balance sheet and financial condition remain strong. Cash on hand was $5.0 million at the end of the quarter, as compared to $8.4 million at the end of the first quarter last year. Working capital was $24.8 million, as compared to $24.0 million at the end of the first quarter last year. Borrowings under the Company's revolving credit facility were $4.9 million at the end of the quarter, as compared to $6.1 million at the end of the first quarter last year, and total bank borrowings were $9.8 million, as compared to $9.7 million at the end of the first quarter last year.

In May 2013, the Company changed its corporate banking relationship and moved to a larger credit facility that provides increased limits and flexibility to better handle the Company's projected future cash needs. The new facility provides for a 3-year revolving credit facility that allows outstanding advances of up to $20 million, as compared to the previous limit of $15 million, and new 7-year term debt of $5 million, which replaced outstanding term debt of $3.5 million.

"We had an excellent quarter, both domestically and internationally," said David M. Rausch, Kewaunee's President and Chief Executive Officer.  "During the quarter, the Company substantially benefited from the favorable timing of several projects. I also am extremely pleased with the performance achieved throughout our organization. In Statesville where Domestic sales were up nearly 20% over the prior year, our Metal Plant and Epoxy Resin Plant produced record shipments, while maintaining high levels of quality and productivity. Our International Operations also had an excellent quarter with sales up nearly 22% over the prior year. Despite these much higher volumes, our Associates continued to do an excellent job in controlling operating costs.

"Looking forward, the Company expects physical year 2014 to perform favorably over fiscal year 2013, although typically we experience variations in results from quarter-to-quarter due to our customers' construction schedules."

Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, storage systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.

The Company's corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets.  One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific's website is located at

Certain statements in this release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, services, and prices.Contact:

D. Michael Parker704/871-3290 Kewaunee Scientific CorporationConsolidated Statements of Operations (Unaudited)(in thousands, except per share data)Three months endedJuly 31,20132012Net sales$
26,683Cost of products sold25,42721,440Gross profit6,5765,243Operating expenses4,1444,138Operating earnings2,4321,105Other income8068Interest expense(88)(114)Earnings before income taxes2,4241,059Income tax expense807371Net earnings1,617688Less: net earnings attributable to the noncontrolling interest3054Net earnings attributable to Kewaunee Scientific Corporation$
34Net earnings per share attributable toKewaunee Scientific Corporation stockholdersBasic$0.61$0.25Diluted$0.61$0.25Weighted average number of common shares outstandingBasic2,5962,581Diluted2,6182,584Kewaunee Scientific CorporationCondensed Consolidated Balance Sheets(in thousands)July 31,April 30,20132013Assets(Unaudited)Cash and cash equivalents$4,408$5,811Restricted Cash619691Receivables, less allowances24,75225,884Inventories12,33413,203Prepaid expenses and other current assets2,0761,641Total Current Assets44,18947,230Net property, plant and equipment14,99515,098Other assets6,6756,414Total Assets$65,859$68,742Liabilities and EquityShort-term borrowings and interest rate swap$5,101$6,997Current portion of long-term debt455200Accounts payable8,23410,406Other current liabilities5,6264,512Total Current Liabilities19,41622,115Other non-current liabilities15,43312,934Total Liabilities34,84935,049Noncontrolling interest2242,017Kewaunee Scientific Corporation equity30,78631,676Total Equity31,01033,693Total Liabilities and Equity$65,859$68,742 

SOURCE Kewaunee Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
2. Kewaunee Scientific Corporation Declares Quarterly Dividend
3. Kewaunee Scientific Reports Record Sales for Second Quarter
4. Kewaunee Scientific Reports Improved Results for Third Quarter
5. Kewaunee Scientific Announces CEO Retirement and Appointment of Successor
6. Donald F. Shaw Elected To Kewaunee Scientific Board Of Directors
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
9. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... United States District Court of Connecticut on behalf of a home health care worker ... all current or former home health care workers employed by Humana, Inc., Humana at ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an ... is being more and more widely heralded as a breakthrough for performing hernia repairs. ... has over traditional laparoscopic surgery is that it can greatly reduce the pain that ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become ... invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, the ... Wimbledon Athletics Facebook page to educate the public, parents and school ... About 2,000 people under the age of 25 die from sudden cardiac arrest ...
Breaking Medicine News(10 mins):